Bloom Health Partners Completes Fiscal Q1 2022 with $5.8M in Revenue and Maintains Guidance for Full Fiscal Year

Bloom Health Partners Completes Fiscal Q1 2022 with $5.8M in Revenue and Maintains Guidance for Full Fiscal Year

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces Q1 Fiscal 2022 revenues of C$5.8M for the period ended December 31st, 2021.

Bloom completed Fiscal Q1 2022 with revenue of C$5.8M and C$5.1M in cash. The Company completed this quarter with a loss from operations of C$1M, which is largely attributed to an investment in expansion and a lower revenue quarter due to cyclical factors. The full report and financial statements are available under the profile for the Company on www.sedar.com.

As previously announced on February 9, 2022, Bloom anticipates Fiscal Year 2022 revenues of C$25M - $28M from continued business with new and existing clients and markets. The Company also expects positive EBITDA(1) from operations in Fiscal 2022.

"Our Q1 Fiscal 2022 set the stage for growth," said Andrew Morton, CEO of Bloom. "We made investments in expansion in Dallas, Atlanta and Alabama as a result of client opportunities and contracts. Our lab business and evolution with clients to Operational Health combined with our 'Bloom Shield' health-tech software platform continues to show good momentum. With two short months in US operations due to Thanksgiving and Christmas falling in Q1 Fiscal 2022, we're pleased to announce revenues of C$5.8M. We're executing on our vision of keeping businesses and organizations running with Operational Health and Health-Tech."

Non-IFRS Financial Measures

We believe that providing certain non-IFRS financial measures provide users with important information regarding the operational performance of our business. The non-IFRS financial measures used by management do not have any standardized meaning prescribed by IFRS and therefore may not be comparable to similar measures presented by other issuers. Accordingly, these measures should not be considered as a substitute or alternative for IFRS measures as determined in accordance with IFRS. By considering these measures in combination with the comparable IFRS financial measures, we believe that users are provided a better overall understanding of our business and financial performance during the relevant period than if they considered the IFRS financial measures alone.

EBITDA

EBITDA is defined as earnings before interest, income taxes, depreciation, and amortization and is utilized by management to assess and evaluate the financial performance of its operations. Management believes that EBITDA improves comparability between periods by eliminating the impact of interest, income taxes, depreciation, and amortization.

Disclosure on Financial Guidance

Anticipated revenue figures and EBITDA are based on modelling and estimates developed by management and updated as of February 28th, 2022. These estimates are based on our Fiscal Year 2021 results and year to date for Fiscal Year 2022, including market size, and assume only ongoing business with announced contracts with Texas and Alabama schools, as well ongoing business with Film/TV productions and existing Fortune 500 clients, as well as marginal growth in fixed costs through Fiscal Year 2022. Readers are cautioned that actual results could differ materially from these estimates based on increases in operating costs, failure to maintain regulatory licensing, inability to execute on existing contracts with schools in Texas and Alabama, failure to attract and retain qualified employees, or a reduction in customer demand.

About Bloom Health Partners Inc.

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) is a global platform for healthcare security, diagnostic testing and occupational health-tech. Our mission is to ensure that "unstoppable is possible" for businesses and their employees through innovative, customized healthcare models. Bloom offers a system for businesses and organizations that helps engage employees and creates strategies to manage health and safety. Our stable, scalable system is an integrated health-tech platform that securely manages data while delivering comprehensive workplace health and safety outcomes.

For more information: investors@bloomhealthpartners.com

On behalf of the board of directors,

Bloom Health Partners Inc.

Andrew Morton, Chief Executive Officer

Forward-Looking Statements

This news release includes forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in the Company's forward-looking statements include the potential that milestones may not be satisfied, acquisitions may not achieve expected benefits, financing requirements, and the other risk factors described in the Company's filings with Canadian securities regulators on www.sedar.com. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/115355

News Provided by Newsfile via QuoteMedia

BLMH:CNX
The Conversation (0)
Bloom Health Partners Announces Leadership Transition

Bloom Health Partners Announces Leadership Transition

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of diagnostic and health technology services, announces a leadership transition.

Effective September 30, 2022, Andrew Morton has stepped down as CEO of the Company to pursue other opportunities. Rosemary Elliston, COO of the Company, has been appointed to the position of Interim CEO. Mr. Morton will continue to support the Company as a Director.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Bloom Health Partners Announces New Location in Hawaii

Bloom Health Partners Announces New Location in Hawaii

New Bloom lab will support operations in the Honolulu area and surrounding region

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces the opening of a new location in in the Honolulu area.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Bloom Health Partners CEO to Speak at Health Benefits Nation Conference in Orlando

Bloom Health Partners CEO to Speak at Health Benefits Nation Conference in Orlando

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces its CEO, Andrew Morton, will speak on a panel at Health Benefits Nation Conference in Orlando, Florida on September 15th, 2022.

Mr. Morton will join co-panelists Eric Hargan, former U.S. Federal Deputy Secretary of the Department of Health and Human Services (DHHS), and Jeff Hogan, President of Upside Health Advisors. The panel titled "Incorporating Occupational Health into Value Based Health Strategies" will focus on workplace health and using data models to improve outcomes in occupational health in such areas as preventive care and mental health.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Bloom Health Partners Reports Profitable Fiscal Q3 2022 with $8.4 Million in Revenue

Bloom Health Partners Reports Profitable Fiscal Q3 2022 with $8.4 Million in Revenue

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces unaudited Fiscal Q2 2022 revenues of CAD $8.4M for the three months ended June 30th, 2022, bringing year-to-date revenues to CAD $24.9M for the first three quarters of Fiscal 2022.

Highlights in Fiscal Q2 2022:

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Bloom Health Partners Announces New Location to Serve Chicago and Surrounding Area

Bloom Health Partners Announces New Location to Serve Chicago and Surrounding Area

New Bloom lab in the Chicago area will serve as a foothold in the midwestern United States

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D84) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces the opening of a new location in the Chicago area.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Cleo Diagnostics CEO Richard Allman.

Cleo’s Biomarker Detection Tech for Ovarian Cancer is a Game Changer for Women, CEO Says

Cleo Diagnostics (ASX:COV) CEO Richard Allman says the company’s patented blood test technology will enable the early diagnosis of ovarian cancer and increase the cancer survival rate for women.

“Ovarian cancer, like most solid tumors, can be very successfully treated with surgery if it's caught early,” he said. "The success rate for surgery for Stage 1 ovarian cancer is over 90 percent. And one of the things that we are very excited about is that our prototype test data for early stage cancer is extremely promising. And we are hoping that this technology will be a game changer for women."

As the company moves toward commercialisation of its technology, Allman said it is important to compare Cleo’s products with the existing gold standard methods through clinical studies.

Keep reading...Show less

Knight Therapeutics Inc. ranks on The Globe and Mail's fifth-annual Women Lead Here benchmark of executive gender diversity

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company") is pleased to announce it will be recognized on The Globe and Mail's 2024 Report on Business magazine's fifth annual Women Lead Here list. This annual editorial benchmark identifies top-level Canadian businesses with the highest executive gender diversity.

The Women Lead Here benchmark was established in 2020 by Report on Business magazine and applies a proprietary research methodology to provide an overview of the largest Canadian corporations with the highest degree of gender diversity among executive ranks. The ranked companies have made tangible and organizational progress related to executive gender parity.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

  • Initiated enrollment of the BACKBEAT global pivotal study evaluating AVIM therapy (also known as BackBeat Cardiac Neuromodulation Therapy) in hypertensive pacemaker patients in collaboration with Medtronic, plc (NYSE: MDT) in December 2023
  • Orchestra BioMed and Terumo remain actively engaged to update operational plans and financial arrangements for Virtue ® Sirolimus AngioInfusion TM Balloon ("SAB") development and commercialization for treatment of coronary and peripheral artery disease
  • Expected runway of cash and cash equivalents and marketable securities, including certain potential future proceeds sufficient into 2H 2026, beyond anticipated BACKBEAT top-line results readout

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2023 financial results and provided a fourth quarter business update.

"2023 was a year of strong momentum for Orchestra BioMed as we made significant progress on our cardiovascular pipeline with the achievement of key regulatory milestones and completion of our successful Nasdaq listing," commented David Hochman, chairman, chief executive officer and founder of Orchestra BioMed. "In December, we initiated the BACKBEAT global pivotal study evaluating our lead program, AVIM therapy, in hypertensive pacemaker patients working alongside our strategic partner Medtronic, the global market leader in cardiac pacing therapies. We see a substantial market opportunity for AVIM therapy in this patient population, as well as in other high-risk hypertension populations."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Medtronic announces FDA approval of newest-generation Evolut TAVR system for treatment of symptomatic severe aortic stenosis

The Evolut™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Cleo Diagnostics

Peer-Review Further Supports CLEO’s Ovarian Cancer Detection Technology

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the publication of further data on its triage test for ovarian cancer.

Keep reading...Show less

U.S. Patent Office rejects Axonics' latest challenge to Medtronic patents

Medtronic moves for patent infringement litigation to resume

Medtronic (NYSE:MDT), the global leader in healthcare technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed the validity of claims in two of its patents in an ongoing patent infringement lawsuit filed by Medtronic against Axonics over sacral neuromodulation (SNM) technologies. Cumulatively, the PTAB has now upheld the validity of five of the Medtronic patents at issue in this lawsuit.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×